NCT07055594View on ClinicalTrials.gov

A Study to Investigate Safety and Preliminary Efficacy of SOA101 in Adult Subjects With Advanced Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 30, 2025

Primary Completion Date

February 29, 2028

Study Completion Date

December 31, 2028

Conditions

Solid Tumors

Interventions

DRUG

SOA101

Participants will receive SOA101. The RP2D will be determined based on the results of the Phase I study. During the dose expansion phase, participants will receive SOA101 at the RP2D regimen.

Trial Locations (1)

Unknown

RECRUITING

China Medical University Hospital, Taichung

All Listed Sponsors

lead

Shine-On Biomedical Co., Ltd.

INDUSTRY